Rosetta Lifecare signed with Enzolytics Inc. agreement on exclusive distribution rights for the distribution of their ITV1 product for the treatment of HIV / AIDS and Hepatitis C for the following countries: Pakistan, United Arab Emirates, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda Northern Sudan, Egypt, Morocco and Tunisia. The drug is in an inspection form based on the IPF platform and has shown very good results in clinical trials.

Rosetta Lifecare Bulgaria LTD About Us

About Us


Rosetta Lifecare Bulgaria LTD is a drug and food supplements distributor, committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.

We, at Rosetta Lifecare Bulgaria LTD, are proud to introduce EnzoImmune Active, an innovative dietary supplement which will help into leading healthy and happy life. We are always committed by Research & Development to bring out the new formulations and the best quality products to serve mankind.

Rosetta Lifecare Bulgaria LTD is partnering with companies with long-term experience in protein isolation and purification in immunochemistry and biochemistry along with experience in repetition with therapeutic proteins used in HIV and cancer.

We also possess experience in the preparation of an application for a nutraceutical compound supplement.

How we help


Our flagship compound EnzoImmune Active is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV, cancer, and many infectious and some autoimmune diseases.

IPF is the active drug substance of EnzoImmune Active and is a purified extract of pepsin. EnzoImmune Active has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications.

It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.

Rosetta Lifecare Bulgaria LTD How We Help

How does IPF work

2 modes of action: Directly prevents CD4 T T-cells. Activates the Th1 immune response, i.e., turns on macrophages that actually ingest tumor itself, killer T actually T-lymphocytes that destroy abnormal cells.

Mode 1

By binding to specific proteins onthe outer surface of tumor particles, Enzolytic IPF directly prevents infecting CD4 T-cells. With IPF, without IPF. gp120 binds to CD4 on T-cells and then to a coreceptor. Causes gp41 attachment to the cell. IPF inactivates gp120 and gp41.

Enzoimmune Active Mode One

Mode 2

Enzolytic IPF binds to T-cells and turns on Th1 immune system responses that kill infected cells. Cytokines and IPF. IFN-y, IL-2 and TNF – are cytokines, small proteins released by T-cells and received by other cells to generate a specific immune response.

Enzoimmune Active Mode Two

IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INF-y, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC – proteins. IPF appears to present a novel mechanism to stimulate innate immune responses.

Rosetta Lifecare Bulgaria LTD Technology Summary

Technology Summary


The immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens. CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.

We have isolated IPF that is the most extensively studied CD 56 ligand to date. We have tested these compounds for their ability to stimulate human NKT cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor.

While the majority of the studies performed focus on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat cancer.

Meet Our Leadership

Valentin Dimitrov

Valentin Dimitrov
Partner, Group Chairman, Chief Managing Director

Graduated from Sofia University, with more than 30 years experience on leading managing positions in the chemical and biotechnological industries.

Milen Dimitrov

Milen Dimitrov
Partner, Managing Director

Graduated with Honors from Richmond University, UK in Finance. Executive Director of Chimco Industries AD.

Abdul Moeez Khan

Abdul Moeez Khan
Partner, Sales Director

Graduated Pharmacy majoring Synthesis of Drugs and MBA in Marketing from the Bombay University, India. More than 34 years of experience in the Pharmaceutical Industry on key positions in Asia and Africa.

Nailesh Shah

Nailesh Shah

Graduated Commerce from Sydenham College of Business and Economics, Mumbai, India. With more than 33 years in pharmaceutical and veterinary industry. Founder of Baader Schulz Laboratories, India, Rosetta Lifecare Pvt. LTD, India, Rank Animal Healthcare Pvt. LTD, Sri Lanka.

Evelina Dimitrova

Evelina Dimitrova
Public Relations Expert

Graduated Psychology, Media and Communications from San Diego State University, USA.